← 返回

靶向 CD11c+髓系细胞群中的聚糖硫酸化可抑制早期 KRAS 突变型肺肿瘤发生

英文原题:Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia.

查看英文原题

Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia.

PubMed 2021/10/26(内容时间) Neoplasia Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

早期肺癌的发展可能受到促进肿瘤生长和侵袭的宿主先天细胞机制的调控。我们最近发现,将糖胺聚糖硫酸化酶 N-脱乙酰酶/N-磺基转移酶-1(Ndst1;参与硫酸乙酰肝素生物合成)的功能丧失突变靶向抗原呈递细胞(APC),可能会增强获得性抗肿瘤 T 细胞免疫机制。将该突变(Ndst1f/f CD11cCre+)与诱导性自发 Kras 突变肺癌模型 [CCSP-rtTA;(tetO7)CMV-Kras-G12D] 杂交,使我们能够研究 APC 突变如何影响早期肺癌的形成和生长。

我们检查了该模型中早期支气管中心性腺瘤的形成,发现此类事件的发生频率在突变背景下显著降低。这与肿瘤相关 FOXP3+ 细胞浸润和 CD163+ M2 型巨噬细胞浸润的显著减少相关。这些变化发生在效应 CD8+ T 细胞浸润肿瘤之前。这种独特的糖胺聚糖硫酸化不足突变对抑制早期 Kras G12D 突变支气管中心性腺瘤形成的影响,以及参与抑制性 T 调节细胞信号传导的细胞(FOXP3+ 细胞)或促进肿瘤的 M2 巨噬细胞功能细胞(CD163+ 细胞)对肿瘤浸润受抑制的细胞表型,为糖胺聚糖靶向如何在早期肺肿瘤发展过程中调控先天细胞机制提供了见解。这些发现还可能影响未来以宿主为中心的免疫抗肿瘤治疗策略的设计。

展开英文摘要原文

Early lung carcinoma development may be modulated by innate host cellular mechanisms that promote tumor growth and invasion.

We recently identified how a loss-of-function mutation in the glycan sulfating enzyme N-deacetylase/N-sulfotransferase-1 (Ndst1; involved in heparan sulfate biosynthesis) targeted to antigen presenting cells (APCs) may augment acquired anti-tumor T cell immune mechanisms. Crossing this mutation (Ndst1f/f CD11cCre+) onto a model of inducible spontaneous Kras mutant lung cancer [CCSP-rtTA; (tetO7) CMV-Kras-G12D] allowed us to examine how the APC mutation affects the formation and growth of early lung carcinoma.

We examined early bronchocentric adenoma formation in the model, and the frequency of such events was significantly reduced on the mutant background. This was associated with significant reductions in tumor associated FOXP3+ cellular infiltration and CD163+ M2-type macrophage infiltration. The findings evolved prior to effector CD8+ T cell infiltration into tumors.

The impact of this unique glycan under-sulfating mutation on inhibiting early Kras G12D mutant bronchocentric adenoma formation along with a cellular phenotype of inhibited tumor infiltration by cells involved in suppressive T-regulatory cell signaling (FOXP3+ cells) or tumor-permissive M2 macrophage functions (CD163+ cells) provides insight on how glycan targeting may modulate innate cellular mechanisms during early lung tumor development. The findings may also impact the future design of host-centered immunologic anti-tumor therapeutic strategies.

论文信息

作者
Kim SY、Johns SC、Gupta P、Varki N、Fuster MM
第一作者单位
Department of Medicine, Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, CA, USA; VA San Diego Healthcare System, Medical and Research Sections, La Jolla, CA, USA.Germany
通讯作者单位
VA San Diego Healthcare System, Medical and Research Sections, La Jolla, CA, USA; Department of Medicine, Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, CA, USA; Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA; Veterans Medical Research Foundation, San Diego, CA, USA. Electronic address: mfuster@health.ucsd.edu.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究 · 美国政府(非公共卫生署)资助研究
期刊
Neoplasia (New York, N.Y.)2021 Nov
原文标识
PubMed 34715561 · DOI 10.1016/j.neo.2021.09.008